Sun Xu-Ren, Sun Zhe, Zhu Zhi, Guan Hai-Xia, Li Chen-Yan, Zhang Jun-Yan, Zhang Yi-Ning, Zhou Huan, Zhang Hui-Jing, Xu Hui-Mian, Sun Ming-Jun
Xu-Ren Sun, Yi-Ning Zhang, Ming-Jun Sun, Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
World J Gastroenterol. 2015 May 7;21(17):5336-44. doi: 10.3748/wjg.v21.i17.5336.
To investigate the expression and prognostic role of pyruvate dehydrogenase (PDH) in gastric cancer (GC).
This study included 265 patients (194 male, 71 female, mean age 59 years (range, 29-81 years) with GC who underwent curative surgery at the First Affiliated Hospital of China Medical University from January 2006 to May 2007. All patients were followed up for more than 5 years. Patient-derived paraffin embedded GC specimens were collected for tissue microarrays (TMAs). We examined PDH expression by immunohistochemistry in TMAs containing tumor tissue and matched non-neoplastic mucosa. Immunoreactivity was evaluated independently by two researchers. Overall survival (OS) rates were determined using the Kaplan-Meier estimator. Correlations with other clinicopathologic factors were evaluated by two-tailed χ(2) tests or a two-tailed t-test. The Cox proportional-hazard model was used in univariate analysis and multivariate analysis to identify factors significantly correlated with prognosis.
Immunohistochemistry showed that 35.47% of total cancer tissue specimens had cytoplasmic PDH staining. PDH expression was much higher in normal mucosa specimens (75.09%; P = 0.001). PDH expression was correlated with Lauren grade (70.77% in intestinal type vs 40.0% in diffuse type; P = 0.001), lymph node metastasis (65.43% with no metastasis vs 51.09% with metastasis; P = 0.033), lymphatic invasion (61.62% with no invasion vs 38.81% with invasion; P = 0.002), histologic subtypes (70.77% in intestinal type vs 40.0% in diffuse type; P = 0.001) and tumor-node-metastasis (TNM) stage (39% in poorly differentiated vs 65.91% in well differentiated and 67.11% in moderately differentiated; P = 0.001) in GC. PDH expression in cancer tissue was significantly associated with higher OS (P < 0.001). The multivariate analysis adjusted for age, Lauren classification, TNM stage, lymph node metastasis, histological type, tumor size, depth of invasion and lymphatic invasion showed that the PDH expression in GC was an independent prognostic factor for higher OS (HR = 0.608, 95%CI: 0.504-0.734, P < 0.001).
Our study indicated that PDH expression is an independent prognostic factor in GC patients and that positive expression of PDH may be predictive of favorable outcomes.
探讨丙酮酸脱氢酶(PDH)在胃癌(GC)中的表达及其预后作用。
本研究纳入了2006年1月至2007年5月在中国医科大学附属第一医院接受根治性手术的265例GC患者(男性194例,女性71例,平均年龄59岁(范围29 - 81岁))。所有患者均随访5年以上。收集患者来源的石蜡包埋GC标本用于组织芯片(TMA)。我们通过免疫组织化学检测TMA中肿瘤组织及配对的非肿瘤黏膜中PDH的表达。由两名研究人员独立评估免疫反应性。采用Kaplan-Meier法计算总生存率(OS)。通过双尾χ(2)检验或双尾t检验评估与其他临床病理因素的相关性。在单因素分析和多因素分析中使用Cox比例风险模型来确定与预后显著相关的因素。
免疫组织化学显示,在全部癌组织标本中,35.47%有细胞质PDH染色。PDH在正常黏膜标本中的表达更高(75.09%;P = 0.001)。PDH表达与Lauren分级相关(肠型中为70.77%,弥漫型中为40.0%;P = 0.001)、淋巴结转移相关(无转移者中为65.43%,有转移者中为51.09%;P = 0.033)、淋巴管浸润相关(无浸润者中为61.62%,有浸润者中为38.81%;P = 0.002)、组织学亚型相关(肠型中为70.77%,弥漫型中为40.0%;P = 0.001)以及GC中的肿瘤-淋巴结-转移(TNM)分期相关(低分化中为39%,高分化中为65.91%,中分化中为67.11%;P = 0.001)。癌组织中PDH表达与较高的OS显著相关(P < 0.001)。多因素分析校正了年龄、Lauren分类、TNM分期、淋巴结转移、组织学类型、肿瘤大小、浸润深度和淋巴管浸润,结果显示GC中PDH表达是较高OS的独立预后因素(HR = 0.608,95%CI:0.504 - 0.734,P < 0.001)。
我们的研究表明,PDH表达是GC患者的独立预后因素,且PDH阳性表达可能预示良好预后。